alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › anti-a-antibodies

anti-a-antibodies

5 studies tagged anti-a-antibodies, dated 2014-05-07 to 2026-07-29. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Advances in modified anti-Aβ antibodies for the treatment of Alzheimer's disease 2026-07-29
  2. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects 2023-08-14
  3. An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease 2018-07-11

Studies

5 studies carry this tag.

Date range

2014 to 2026

Top journals

  • Acta neuropathologica 1
  • BMC medicine 1
  • Journal of Alzheimer's disease reports 1
  • Nature communications 1
  • Neurobiology of disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Advances in modified anti-Aβ antibodies for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. BMC medicine 2026-07-29 Treatments

    Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder, the treatment of which remains a major clinical challenge.

  2. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease reports 2023-08-14 Treatments

    Immunotherapeutic efforts to slow the clinical progression of Alzheimer's disease (AD) by lowering brain amyloid-β (Aβ) have included Aβ vaccination, intravenous immunoglobulin (IVIG) products, and anti-Aβ monoclonal antibodies.

  3. An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Nature communications 2018-07-11 Treatments

    Although the amyloid β-protein (Aβ) is believed to play an initiating role in Alzheimer's disease (AD), the molecular characteristics of the key pathogenic Aβ forms are not well understood.

  4. Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of disease 2015-07-26 Treatments

    Compelling genetic evidence links the amyloid precursor protein (APP) to Alzheimer's disease (AD).

  5. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Acta neuropathologica 2014-05-07 Treatments

    Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer's disease (AD) is currently the advocated clinical strategy for treating this disease.

All topic tags with their study counts